natgillin/translations-raw huggingface dataset:
Blisters: 10 or 30 capsules.
Blisteri: 10 ili 30 kapsula.
Tell your doctor if you are taking: - medicines for depression or anxiety such as venlafaxine, maprotiline and desipramine.
- lijekove za depresiju ili tjeskobu poput venlafaksina, maprotilina i dezipramina.
Bottles: 10, 30 or 90 capsules.
Boce: 10, 30 ili 90 kapsula.
- if you have a tumour of the adrenal gland (known as phaeochromocytoma), or of the nervous system (known as paraganglioma), or any other tumour which increase the risk of severe high blood pressure; - if you have ever suffered from neuroleptic malignant syndrome which is a rare reaction to antipsychotic medicines; - if you have ever suffered from a rare muscle disorder called rhabdomyolysis which was not caused by injury; - if you are taking certain antidepressants called monoamine-oxidase (MAO) inhibitors (e.g. phenelzine, tranylcypromine or moclobemide).
- ako ste ikad imali maligni neuroleptički sindrom, rijetku reakciju na antipsihotičke lijekove - ako ste ikad imali rijetki mišićni poremećaj koji se naziva rabdomioliza koji nije bio uzrokovan ozljedom;
The pharmacokinetics of opicapone was evaluated in elderly subjects (aged 65-78 years old) after 7day multiple-dose administration of 30 mg. An increase in both the rate and extent of systemic exposure was observed for the elderly population when compared to the young population.
Farmakokinetika opikapona procjenjivana je u starijih ispitanika (u dobi 65-78 godina) nakon višekratne primjene doze od 30 mg tijekom 7 dana.
Do not drive or operate machinery if you experience any of these side effects.
Ako osjetite ove nuspojave, nemojte upravljati vozilima ili raditi sa strojevima.
Bottles: 10 or 30 capsules.
Boce: 10 ili 30 kapsula.
Other levodopa medicines
Drugi lijekovi koji sadrže levodopu
In vitro studies have shown that opicapone is not transported by OATP1B1, but is transported by OATP1B3, and efflux transported by P-gp and BCRP.
In vitro ispitivanja pokazala su da se opikapon ne transportira pomoću OATP1B1, ali se transportira pomoću
Entacapone (N=122)
Entakapon (N=122)
INSTRUCTIONS ON USE
Ne preporučuje se koristiti
Dose adjustments of antiparkinsonian therapy
Prilagođavanje doze lijekova za liječenje Parkinsonove bolesti
Opicapone demonstrated clinical efficacy superior to placebo during the double-blind treatment, both for the primary efficacy variable used in both pivotal studies, i.e. reduction in OFF-time (Table 2), the proportion of OFF-time responders (i.e. a subject who had a reduction in OFF-time of at least 1 hour from baseline to endpoint) (Table 3) and for most diary derived secondary endpoints.
Opikapon je pokazao bolju kliničku djelotvornost u usporedbi s placebom tijekom dvostruko slijepog ispitivanja, kako za varijablu primarne djelotvornosti korištene u oba ključna ispitivanja, tj. smanjenje OFFvremena (Tablica 2), udio respondera (bolesnika s postignutim odgovorom) s obzirom na OFF-vrijeme (npr.
Hypertension, Hypotension
Krvožilni poremećaji ortostatska hipotenzija hipertenzija, hipotenzija
There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh Class B).
Klinička iskustva s primjenom u bolesnika s umjerenim oštećenjem funkcije jetre (stupanj B prema ChildPughovoj klasifikaciji) su ograničena.
Common: may affect up to 1 in 10 people - constipation - dry mouth - vomiting (being sick) - increased levels of the enzyme (creatine kinase) in your blood - muscle spasm
- povraćanje - povećane razine enzima (kreatin kinaze) u krvi - mišićni grčevi
Ongentys 50 mg hard capsules are dark blue, approximately 19 mm length, with “OPC 50” and “Bial” printed on the capsules.
Ongentys 50 mg tvrde kapsule su tamnoplave boje, duge oko 19 mm, s otisnutim „OPC 50” i „Bial” na kapsuli.
Weight decreased
Tjelesna težina
Dysgeusia, Hyperkinesia, Syncope
Poremećaji živčanog sustava diskinezija omaglica, glavobolja, somnolencija disgeuzija, hiperkinezija, sinkopa
OPA/Al/PVC//Al blisters containing 10, 30 or 90 capsules Not all pack sizes may be marketed.
Blisteri OPA/Al/PVC//Al koji sadrže 10, 30 ili 90 kapsula.
Ongentys 25 mg hard capsules are light blue, approximately 19 mm length, with “OPC 25” and “Bial” printed on the capsules.
Ongentys 25 mg tvrde kapsule su svijetloplave boje, duge oko 19 mm, s otisnutim „OPC 25” i „Bial” na kapsuli.
Patients had disease severity stages 1 to 3 (modified Hoehn and Yahr) at ON, were treated with 3 to 8 daily doses of levodopa/DDCI and had a daily average OFF-time of at least 1.5 hours.
Bolesnici su imali stupanj težine bolesti 1 do 3 (prema modificiranoj ljestvici Hoehn-Yahr) u dijelu dana kad su simptomi bolesti bili dobro kontrolirani lijekovima (engl.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM I UNUTARNJEM PAKIRANJU BOCA OD HDPE
Muscle twitching, Musculoskeletal stiffness, Myalgia, Pain in extremity
mišićno-koštana ukočenost, mialgija,
Decreased appetite, Hypertriglyceridaemia
Poremećaji metabolizma i prehrane oslabljeni apetit, hipertrigliceridemija
No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A).
Nije potrebno prilagođavanje doze u bolesnika s blagim oštećenjem funkcije jetre (stupanj A prema Child
Patients and care-givers should be made aware that impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments.
Bolesnike i osobe koje se o njima brinu potrebno je uputiti da bolesnici koji se liječe agonistima dopamina i/ili drugim dopaminergicima mogu razviti poremećaje kontrole poriva, uključujući patološko kockanje,
Ongentys is for oral use.
Ongentys se primjenjuje kroz usta.
N LS mean
N LS srednja vrijednost
See leaflet for further information.
Za više informacija pogledati u uputi o lijeku.
Ongentys 25 mg hard capsules
Ongentys 25 mg tvrde kapsule
Each hard capsule contains 25 mg of opicapone.
Jedna tvrda kapsula sadrži 25 mg opikapona.
There is no clinical experience in patients with severe hepatic impairment (Child-Pugh Class C) (see section 4.2).
Nema kliničkog iskustva o primjeni u bolesnika s teškim oštećenjem funkcije jetre (stupanj C prema Child
Each hard capsule contains 50 mg of opicapone.
Jedna tvrda kapsula sadrži 50 mg opikapona.
Eye disorders
- začepljenost uha
Ongentys 50 mg hard capsules
Ongentys 50 mg tvrde kapsule
EU/1/15/1066/001 10 hard capsules EU/1/15/1066/008 30 hard capsules
EU/1/15/1066/001 10 tvrdih kapsula EU/1/15/1066/008 30 tvrdih kapsula
EU/1/15/1066/005 10 hard capsules EU/1/15/1066/006 30 hard capsules EU/1/15/1066/007 90 hard capsules
EU/1/15/1066/005 10 tvrdih kapsula EU/1/15/1066/006 30 tvrdih kapsula EU/1/15/1066/007 90 tvrdih kapsula
Opicapone showed a marked (>90%) and long-lasting (>24 hours) COMT inhibition in healthy subjects after administration of 50 mg opicapone.
Nakon primjene 50 mg opikapona u zdravih ispitanika, opikapon je pokazao izrazitu (>90%) i dugotrajnu inhibiciju COMT-a (> 24 h).
Ongentys 25 mg capsules opicapone
Ongentys 25 mg kapsule opikapon
EU/1/15/1066/009 10 hard capsules EU/1/15/1066/010 30 hard capsules
EU/1/15/1066/009 10 tvrdih kapsula EU/1/15/1066/010 30 tvrdih kapsula
White high density polyethylene (HDPE) bottles with polypropylene (PP) child resistant closures containing 10 or 30 capsules.
Bijele boce od polietilena visoke gustoće (HDPE) sa zatvaračem od polipropilena (PP) sigurnim za djecu,
Package leaflet: Information for the patient Ongentys 25 mg hard capsules opicapone This medicine is subject to additional monitoring.
Uputa o lijeku: Informacije za bolesnika Ongentys 25 mg tvrde kapsule opikapon
EU/1/15/1066/002 10 hard capsules EU/1/15/1066/003 30 hard capsules EU/1/15/1066/004 90 hard capsules
EU/1/15/1066/002 10 tvrdih kapsula EU/1/15/1066/003 30 tvrdih kapsula EU/1/15/1066/004 90 tvrdih kapsula
Hepatic impairment
- omaglica - glavobolja
Concomitant use with monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine and moclobemide) other than those for the treatment of Parkinson's disease (see section 4.5).
tranilciprominom i moklobemidom) osim onih namijenjenih liječenju Parkinsonove bolesti (vidjeti dio 4.5).
Light blue capsules, size 1, approximately 19 mm, imprinted “OPC 25” on the cap and “Bial” on the body.
Kapsule svijetloplave boje, veličine 1, duge oko 19 mm, s otisnutim „OPC 25” na kapici i „Bial” na tijelu kapsule.
Each capsule contains 25 mg of opicapone.
Jedna kapsula sadrži 25 mg opikapona.
Ongentys 50 mg capsules opicapone
Ongentys 50 mg kapsule opikapon
Opicapone demonstrated clinical efficacy superior to placebo during the double-blind treatment, both for the primary efficacy variable used in both pivotal studies, i.e. reduction in OFF-time (Table 2), the proportion of OFF-time responders (i.e. a subject who had a reduction in OFF-time of at least 1 hour from baseline to endpoint) (Table 3) and for most diary-derived secondary endpoints.
Opikapon je pokazao bolju kliničku djelotvornost u usporedbi s placebom tijekom dvostruko slijepog ispitivanja, kako za varijablu primarne djelotvornosti korištene u oba ključna ispitivanja, tj. smanjenje OFF
Dark blue capsules, size 1, approximately 19 mm, imprinted “OPC 50” on the cap and “Bial” on the body.
Kapsule tamnoplave boje, veličine 1, duge oko 19 mm, s otisnutim „OPC 50” na kapici i „Bial” na tijelu kapsule.
Opicapone exposure increased in a dose proportional manner following once-daily multiple dose administration up to 50 mg opicapone.
Nakon višekratne primjene opikapona u dozi do 50 mg jedanput na dan, izloženost opikaponu povećavala se proporcionalno dozi.
Package leaflet: Information for the patient Ongentys 50 mg hard capsules opicapone This medicine is subject to additional monitoring.
Uputa o lijeku: Informacije za bolesnika Ongentys 50 mg tvrde kapsule opikapon
- muscle spasm - dizziness - headache - sleepiness - difficulty falling or staying asleep - strange dreams - experiencing or seeing things which do not exist (hallucinations) - a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting
- pad krvnog tlaka pri ustajanju koji uzrokuje omaglicu, ošamućenost ili nesvjesticu Manje često: mogu se javiti u do 1 na 100 osoba: - osjećaj lupanja srca ili nepravilni otkucaji srca
How to store Ongentys
Moguće nuspojave Kako čuvati Ongentys
Each capsule contains 50 mg of opicapone.
Jedna kapsula sadrži 50 mg opikapona.
Musculoskeletal and connective tissue disorders
Poremećaji mišićno koštanog sustava i vezivnog tkiva mišićni spazmi trzanje mišića,
Constipation, Dry mouth, Vomiting
- mišićni trzaji, ukočenost ili bol
Ongentys 50 mg hard capsules opicapone
Ongentys 50 mg tvrde kapsule opikapon
Ongentys 25 mg hard capsules opicapone
Ongentys 25 mg tvrde kapsule opikapon
À Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado Portugal (only for outer packaging)
Mamede do Coronado Portugal (samo za vanjsko pakiranje)
Special populations
Posebne populacije bolesnika Starije osobe
Vascular disorders
dekarboksilaze.
Dizziness, Headache, Somnolence
- omaglica - glavobolja - pospanost - otežano uspavljivanje i održavanje spavanja
The dose of other medicines to treat Parkinson's disease may need to be adjusted when you start taking Ongentys.
Kada počnete uzimati Ongentys može biti potrebno prilagoditi doze ostalih lijekova za liječenje Parkinsonove bolesti.
Data were as follows (values in brackets show the 95% confidence intervals):
Podaci su sljedeći (vrijednosti u zagradi pokazuju 95% interval pouzdanosti):
This vaccine is recommended to help to protect you against flu.
Ovo cjepivo je preporučeno kako bi pomoglo zaštititi Vas od gripe.
Detailed information on this vaccine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu.
Children and adolescents INTANZA is not recommended for use in children and adolescents below 18 years.
Djeca i adolescenti INTANZA se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
*In some cases, local redness lasted up to 7 days.
* u nekim je slučajevima lokalno crvenilo bilo prisutno do 7 dana.
Intradermal 15µg A/H3N2
Intradermalna primjena 15μg A/H3N2
You hear a click and a shield comes out to cover the needle.
Čuti ćete „klik“ i štitnik će izaći van i prekriti iglu.
INTANZA is not recommended for use in children and adolescents below 18 years due to insufficient data on safety and efficacy.
INTANZA se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina zbog nedostatnih podataka o sigurnosti primjene i djelotvornosti.
INTANZA is administered to you by your doctor or nurse.
INTANZA će Vam aplicirati liječnik ili medicinska sestra.
What INTANZA is and what it is used for
Što je INTANZA i za što se koristi
What INTANZA looks like and contents of the pack
Kako INTANZA izgleda i sadržaj pakovanja
• Whenever the risk management system is modified, especially as the result of new information is received that may lead to a significant change to benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• Uoči svake izmjene sustava za upravljanje rizicima, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je omjer korist/rizik rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili smanjenja rizika).
Overdose is unlikely to have any untoward effect.
Predoziranje Nije vjerojatno da predoziranje ima bilo kakav nepovoljan učinak.
Date of first authorisation: 24 February 2009 Date of latest renewal: 24 February 2014
Datum posljednje obnove odobrenja 24. veljače 2014.
The use of INTANZA should be based on official recommendations.
INTANZA se mora primjenjivati u skladu sa službenim preporukama.
2/ HOLD MICRO-INJECTION SYSTEM BETWEEN THUMB & MIDDLE FINGER
2/ DRŽITE MIKROINJEKCIJSKI SUSTAV IZMEĐU PALCA I SREDNJEG PRSTA
- Tell your doctor if you have been treated with medicines that may reduce your immune response such as corticosteroids (for example cortisone), medicines against cancer (chemotherapy), radiotherapy or other medicines affecting the immune system.
- Obavijestite svog liječnika ukoliko ste primali lijekove koji mogu smanjiti Vaš imunološki odgovor, kao što su terapija kortikosteroidima (npr. kortizon), terapija za liječenje raka (kemoterapija), radioterapija ili neki drugi lijekovi koji utječu na imunološki sustav.
Pharmacotherapeutic group: Influenza vaccines, ATC code: J07BB02
Farmakoterapijska skupina: cjepivo protiv influence ATK oznaka: J07BB02
When an injection of INTANZA is given, the immune system (body's natural defences) will develop
Kada osoba primi cjepivo INTANZA, imunološki sustav (prirodni tjelesni sustav obrane) stvorit će
Remove the needle cap from the Micro-Injection
Uklonite zatvarač igle s mikroinjekcijskog sustava
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Allergic reactions including generalized skin reactions such as urticaria, anaphylactic reactions, angioedema, shock
Alergijske reakcije uključujući generalizirane reakcije kože kao što su urtikarija, anafilaktička reakcija, angioedem, šok
In this comparative trial the geometric mean titres (GMTs), seroprotection rate*, seroconversion or significant increase rate** and the geometric mean titre ratio (GMTR) for anti-HA antibody (measured by HI) were assessed according to predefined criteria.
U ovoj komparativnoj studiji srednji geometrijski titri (GMT), stopa seroprotekcije*, serokonverzije ili stopa značajnog porasta** te omjer geometrijskog srednjeg titra (GMTR) za anti-HA antitijela (mjereno HI testom) su procijenjeni prema unaprijed određenim kriterijima.
- You should tell your doctor before vaccination if you have a poor immune response (immunosuppression) due to disease or medicines, because the vaccine may not work very well in this case.
- Prije cijepljenja trebali bi obavijestiti liječnika ukoliko imate smanjen imunološki odgovor (imunosupresiju) uzrokovan bolešću ili uzimanjem lijekova jer u tom slučaju cjepivo možda neće biti učinkovito.
Store in refrigerator.
POSEBNE MJERE ČUVANJA Čuvati u hladnjaku.
INTANZA may be given at the same time as other vaccines.
INTANZA se može dati istovremeno s drugim cjepivima.
The data below summarizes the frequencies of the adverse reactions that were recorded following vaccination during clinical trials and worldwide post-marketing experience, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1000); very rare (<1/10,000), not known (cannot be estimated from available data).
Dolje navedeni podaci sažeto prikazuju učestalost nuspojava koje su zabilježene nakon cijepljenja tijekom kliničkih ispitivanja i postmarketinške primjene širom svijeta, prema sljedećim kategorijama: vrlo često ( ≥ 1/10); često ( ≥ 1/100 do < 1/10); manje često ( ≥ 1/1 000 do < 1/100); rijetko ( ≥ 1/10
Posology Individuals 60 years of age and over: 0.1 ml.
Osobe u dobi od 60 godina i starije: 0,1 ml.
What INTANZA is and what it is used for What you need to know before you use INTANZA
Što je INTANZA i za što se koristi Što morate znati prije nego počnete primjenjivati cjepivo INTANZA
INTANZA is given as an injection into the upper layer of the skin (preferably the muscle of the upper
INTANZA se daje kao injekcija u gornji sloj kože (preporučuje se mišić nadlaktice).
INTANZA will help to protect you against the three strains of virus contained in the vaccine, or other strains closely related to them.
INTANZA će Vam pomoći u zaštiti od tri virusna soja sadržana u ovom cjepivu, ili od drugih usko srodnih sojeva.
INTANZA should under no circumstances be administered intravascularly.
INTANZA se ne smije ni u kojem slučaju injicirati intravaskularno.
The safety of INTANZA has been assessed in 3 open-label randomised clinical trials, 3,372 vaccinees received an injection of INTANZA.
Sigurnost primjene cjepiva INTANZA ispitivana je u 3 otvorena randomizirana klinička istraživanja u kojima su 3372 osobe primile injekciju cjepiva INTANZA.
Please read the instruction before use
Prije primjene cjepiva molimo pročitajte upute za uporabu
INTANZA may contain residues of eggs such as ovalbumin and residues of neomycin, formaldehyde and octoxinol 9, which are used during the manufacturing process (see section 4.3).
INTANZA može sadržavati ostatne tvari jaja kao što je ovalbumin i ostatne tvari neomicina, formaldehida i oktoksinola 9, koji su korišteni u proizvodnji lijeka (vidjeti dio 4.3).
Across all three influenza strains, for the comparator intramuscular vaccine GMTs ranged between 34.8 (1/dil) and 181.0 (1/dil), seroprotection rates ranged between 48.9% and 87.9%, seroconversion or significant increase rates ranged between 30.0% and 46.9% and GMTRs ranged between 3.04 and 5.35-fold over baseline HI titres.
U slučaju sva tri soja, kod cjepiva za intramuskularnu primjenu koje je korišteno kao komparator, GMT-i su iznosili između 34,8 (1/dil) i 181,0 (1/dil), seroprotekcijske stope su se kretale između 48,9% i 87,9%, serokonverzija ili stope značajne porasta bile su između 30,0% i 46,9 %, dok su GMTR-i bili od 3,04 do 5,35 puta viši od početnog HI titra.
• Vessel inflammation which may result in very rare cases in temporary kidney problems.
• Upala krvnih žila koja se u vrlo rijetkim slučajevima može očitovati privremenim poteškoćama s
Injection is considered successful whether or not the presence of a
Injiciranje se smatra uspješnim bez obzira da li je na mjestu injiciranja
Systemic safety profile of INTANZA is similar to the comparator vaccine, adjuvanted or nonadjuvanted, administered intramuscularly.
Sistemski sigurnosni profil cjepiva INTANZA sličan je onome kod komparativnog, adjuvantiranog ili neadjuvantiranog cjepivaprimjenjenog intramuskularno.
EU/1/08/505/004 - pack of 1 pre-filled syringe with a Micro-Injection System EU/1/08/505/005 - pack of 10 pre-filled syringes with a Micro-Injection System EU/1/08/505/006 - pack of 20 pre-filled syringes with a Micro-Injection System
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET EU/1/08/505/004 - pakiranje od 1 napunjene štrcaljke s mikroinjekcijskim sustavom EU/1/08/505/005 - pakiranje od 10 napunjenih štrcaljki s mikroinjekcijskim sustavom EU/1/08/505/006 - pakiranje od 20 napunjenih štrcaljki s mikroinjekcijskim sustavom
Talk to your doctor, pharmacist or nurse before using INTANZA.
Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite cjepivo INTANZA.
What you need to know before you use INTANZA
Što morate znati prije nego počnete primjenjivati cjepivo INTANZA
Very limited data in immunocompromised patients are available for INTANZA.
Podaci o primjeni cjepiva INTANZA u imunokompromitiranih pacijenata su ograničeni.
A/Michigan/45/2015 (H1N1)pdm09 - like strain A/Hong Kong/4801/2014 (H3N2) - like strain
A/Michigan/45/2015 (H1N1)pdm09 - sličan soj
This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for
Ovo cjepivo odgovara preporuci SZO (sjeverna hemisfera) i odluci EU za sezonu 2017/2018.
** Seroconversion = negative pre-vaccination HI titre and post vaccination HI titre ≥ 40, Significant increase = positive pre-vaccination HI titre and at least a 4-fold increase in post-vaccination HI titre GMTR: Geometric mean titre ratio of individual (post-/pre-vaccination titre).
*seroprotekcija = HI titar ≥ 40 **serokonverzija = negativni prevakcinacijski HI titar i HI postvakcinacijski titar ≥ 40, Značajan porast = pozitivni prevakcinacijski HI titar i najmanje četverostruki porast u postvakcinacijskom HI
0.1 ml of suspension in a pre-filled syringe (glass) with a Micro-Injection System, with attached micro-needle, equipped with an elastomer plunger stopper (chlorobutyl), a tip cap (thermoplastic elastomer and polypropylene) and a needle shielding system.
0,1 ml suspenzije u napunjenoj štrcaljki (staklo) s mikroinjekcijskim sustavom, s pričvršćenom mikroiglom, opremljenom s elastomernim čepom klipa (klorobutil), zatvaračem vrha (termoplastični elastomer i polipropilen) i sustavom zaštite za iglu.
A/Michigan/45/2015 (H1N1)pdm09 - like strain (A/Michigan/45/2015, NYMC X-275) ................................................................................................................................ 15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B) ................................................................................................................................ 15 micrograms HA** B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) ....................... 15 micrograms HA**
A/Michigan/45/2015 (H1N1)pdm09 - sličan soj (A/Michigan/45/2015, NYMC X-275) ............................................................................................................................. 15 mikrograma HA** A/Hong Kong/4801/2014 (H3N2) - sličan soj (A/Hong Kong/4801/2014, NYMC X-263B) ............................................................................................................................. 15 mikrograma HA** /Brisbane/60/2008 - sličan soj (B/Brisbane/60/2008, divlji tip) ........................ 15 mikrograma HA**
Other vaccines or medicines and INTANZA Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Obavijestite liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koji drugi lijek.